60 second taste gel
ivoclar vivadent ltd - sodium fluoride 2.73%{relative} (2.88%w/w with 6% manufacturers overage.) - topical gel - 2.73% w/w - active: sodium fluoride 2.73%{relative} (2.88%w/w with 6% manufacturers overage.) excipient: carbomer 940 pascal red. flavour enhancer western. 5916-57 fruit mix flavour 53299-93 methyl salicylate phosphoric acid purified water saccharin sodium sodium benzoate vanilla flavour ke 21856
60 second taste gel
ivoclar vivadent ltd - sodium fluoride 2.73%{relative} (2.88% with 6% manufacturers overage.) - topical gel - 2.73% w/w - active: sodium fluoride 2.73%{relative} (2.88% with 6% manufacturers overage.) excipient: brilliant blue fcf carbomer 940 pascal red. enhancer flavour 5916-57 grape flavour 51125-107 phosphoric acid purified water saccharin sodium sodium benzoate
60 second taste gel
ivoclar vivadent ltd - sodium fluoride 2.73%{relative} (2.88% with 6% manufacturers overage.) - topical gel - 2.73% w/w - active: sodium fluoride 2.73%{relative} (2.88% with 6% manufacturers overage.) excipient: carbomer 940 pascal green . peppermint flavour 5873-57 phosphoric acid purified water saccharin sodium sodium benzoate spearmint oil
60 second taste gel
ivoclar vivadent ltd - sodium fluoride 2.73%{relative} (2.88% with 6% manufacturers overage.) - topical gel - 2.73% w/w - active: sodium fluoride 2.73%{relative} (2.88% with 6% manufacturers overage.) excipient: brilliant blue fcf carbomer 940 pascal red. enhancer flavour 5916-57 phosphoric acid purified water raspberry flavour 52464-121 saccharin sodium sodium benzoate vanilla flavour ke 21856
60 second taste gel
ivoclar vivadent ltd - sodium fluoride 2.73%{relative} (2.88% with 6% manufacturers overage.) - topical gel - 2.73% w/w - active: sodium fluoride 2.73%{relative} (2.88% with 6% manufacturers overage.) excipient: allura red ac carbomer 940 pascal red #33 enhancer flavour 5916-57 phosphoric acid purified water saccharin sodium sodium benzoate strawberry flavour 51870-33 vanilla flavour ke 21856
60 second taste gel
ivoclar vivadent ltd - sodium fluoride 2.73%{relative} (2.88% with 6% manufacturers overage.) - topical gel - 2.73% w/w - active: sodium fluoride 2.73%{relative} (2.88% with 6% manufacturers overage.) excipient: carbomer 940 deep orange.47450 enhancer flavour 5916-57 orange flavour (creamsicle) 51445-53 phosphoric acid purified water quinoline yellow saccharin sodium sodium benzoate vanilla flavour ke 21856 zinc oxide
sodium chloride 0.9 % intravenous infusion bp
teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.
sodium chloride 0.9 % intravenous infusion bp
teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.
sodium valproate wockhardt sodium valproate 1000 mg/10 ml solution for injection ampoule
wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.
sodium valproate wockhardt sodium valproate 400 mg/4 ml solution for injection ampoule
wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.